Familial Adenomatous Polyposis Pipeline Review, H2 2020 - Therapeutic Analysis of 12 Companies & 5 Drug Profiles - ResearchAndMarkets.com

DUBLIN--()--The "Familial Adenomatous Polyposis - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Familial Adenomatous Polyposis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 8 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:

Introduction

Report Coverage

  • Familial Adenomatous Polyposis - Overview
  • Familial Adenomatous Polyposis - Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Products under Development by Companies

Familial Adenomatous Polyposis - Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development

  • ADT Pharmaceuticals Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • DNAlite Therapeutics Inc
  • Emtora Biosciences
  • FunPep Co Ltd
  • GLW Pharma
  • Johnson & Johnson
  • Stemsynergy Therapeutics Inc
  • TherapyX Inc
  • Thetis Pharmaceuticals LLC
  • Zikani Therapeutics Inc

Familial Adenomatous Polyposis - Drug Profiles

  • (eflornithine hydrochloride + sulindac) - Drug Profile
  • CLXONC-57 - Drug Profile
  • FAPXIL SR - Drug Profile
  • Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
  • guselkumab - Drug Profile

Familial Adenomatous Polyposis - Dormant Projects

  • Familial Adenomatous Polyposis - Discontinued Products
  • Familial Adenomatous Polyposis - Product Development Milestones

Featured News & Press Releases

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2ushkz

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900